Search

Sarepta Therapeutics Executes Licensing Agreement for Gene Therapy Program from Nationwide Children’s Hospital to Treat Limb-Girdle Muscular Dystrophy Type 2A
Sarepta Therapeutics Announces Second Quarter 2021 Financial Results and Recent Corporate Developments
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program
Sarepta Therapeutics to Present at Upcoming Investor Conferences
Sarepta Therapeutics to Showcase Data from its Gene Therapy and RNA Platforms at World Muscle Society 2021 Virtual Congress
Seroprevalence: What patients should know about pre-existing antibodies to gene therapy
Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Announces Initiation of EMBARK, a Global Pivotal Study of SRP-9001, a Gene Therapy for the Treatment of Duchenne Muscular Dystrophy